Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis

Latest Licensing Deals: 2026 Deal Log

Licensing, collaboration and option deals announced in 2026 with a disclosed total of $1 billion or more, or an upfront of $100 million or more — 72 deals so far, newest first. Each entry was checked against the company announcement or filing linked in the last column. 39 of the 72 have a China-domiciled licensor. Acquisitions are tracked separately in our pharma M&A tracker.

Licensee ← licensor. “Up to” values include milestones that may never be paid. Verified through 19 Oct 2026.

Licensing Market Size: $274B in 2025, $221B Through Q3 2026

J.P. Morgan’s quarterly Biopharma Licensing and Venture Report, built on DealForma’s database, is the most consistent public measure of licensing activity. It counts announced R&D licensing value for therapeutics and platforms, including all disclosed milestones. On that basis, 2025 set a record at $274.3 billion, and 2026 had reached $221.1 billion by the end of September — about $54 billion in the third quarter after a first half of $166.7 billion.

Source: J.P. Morgan Biopharma Licensing and Venture Reports, Q4 2025 to Q3 2026 (DealForma). Each figure is as published in the report covering that period; DealForma revises earlier periods as disclosures are captured — 2025 was reported at “over $252 billion” in December 2025 and $274.3 billion in October 2026.

Top Licensing Deals: 2025–2026

Headline value and upfront cash tell different stories. The biggest headline numbers now come from multi-program portfolios with long milestone tails, while the largest upfronts still mostly go to single assets with clinical data. The table ranks the largest disclosed upfront payments of 2025 and 2026; the largest deals by headline value are listed in the FAQ and the deal log above.

Deal Structure Trends

Understanding the differences between in-licensing and out-licensing starts with the cash profile. Upfront payments were 6% of announced licensing value in 2026, below the 7% of each of the previous three years, so most headline value depends on future development, regulatory and sales milestones. What buyers pay at signing depends heavily on stage.

In-licensing by big pharma, 2026 through Q3. Source: J.P. Morgan Q3 2026 report (DealForma). Phase II and III medians rest on very few deals.

Oncology shows the same gradient over a longer window. Across big pharma oncology deals signed from 2024 to Q3 2026, median upfronts rose from $50 million for platform and discovery assets to $700 million for Phase III programs, and Phase III programs carried the highest median total value at about $1.9 billion. Phase II deals had the largest median milestone packages, at nearly $1.5 billion.

Deals by Therapeutic Area & Modality

Of the 72 deals in our 2026 log, 23 are in oncology, 14 in immunology, 11 in obesity and metabolic disease, 5 in neuroscience, 5 in cardiorenal disease, and 11 are platform or multi-area discovery deals. By modality, J.P. Morgan reports that biologics attracted the most licensing upfront cash and equity in 2026 through Q3, at $4.4 billion, while genomics, sequencing and screening ranked second at $3 billion, up from $682 million in all of 2025.

China-to-West Licensing: Record-Setting Activity

China-originated biotech licensing set a record in 2025: Chinese drugmakers signed $135.7 billion in cross-border out-licensing deals across 157 agreements, up from $51.9 billion across 94 in 2024, according to PharmCube data reported by Caixin. 2026 is running ahead of that pace. VBInsight counted about 240 China licensing deals worth $106.3 billion in the first half alone, $100.4 billion of it outbound, with upfronts of $6.2 billion, or 5.8% of value.

The shift is clearest in big pharma deals with meaningful cash at signing. Through Q3 2026, China-origin assets accounted for 51% of big pharma licensing deals with at least $50 million upfront — 18 deals, against 19 in all of 2025 — and received 65% of the upfront dollars in those deals, or $5.7 billion, according to J.P. Morgan. In our log, 39 of 72 deals, nine of the ten largest by headline value and about 65% of the disclosed upfront cash involve a China-origin licensor. Our China out-licensing report breaks down the 2025 data.

The BIOSECURE Act creates complexity but has not slowed deal-making. BD executives are incorporating BIOSECURE compliance into due diligence rather than avoiding China-origin assets, and manufacturing arrangements that keep production outside designated Chinese companies are becoming standard deal terms.

Licensing vs M&A: Strategic Comparison

BD executives must choose between licensing and acquisition as pipeline-building strategies — a decision explored in our pharma M&A tracker. The two markets are measured differently. Biopharma M&A totaled $138.9 billion of upfront cash across 113 deals through Q3 2026, already above all of 2025. Licensing announced $221.1 billion of headline value in the same period, but at a 6% upfront share that implies only around $13 billion paid at signing.

BD Strategy: Maximizing Deal Value

The 2026 deal flow shows clear patterns that BD teams can use, whether licensing in or licensing out.

Conclusion & Q4 2026 Outlook

By headline value, licensing now outpaces M&A, even though far less cash changes hands at signing. With $221.1 billion announced through September, J.P. Morgan expects 2026 to finish above most historical years; matching 2025’s record would need about $53 billion of announced value in the fourth quarter, and three October deals alone account for over $30 billion of headline value.

Three themes to watch through year-end: whether China-origin assets keep their majority share of large upfronts; whether the portfolio model spreads beyond Chinese licensors; and how much of the year’s milestone-heavy headline value converts into cash as programs reach their first development milestones. Obesity, ADCs and T-cell engagers for autoimmunity remain the most contested categories.

We update this tracker as deals are announced. For new deals, check the 2026 deal log; for the market figures, the next J.P. Morgan report covers the full year.

Frequently Asked Questions

Methodology & Sources

The 2026 deal log includes licensing, collaboration and option agreements announced between 1 January and 19 Oct 2026 with a disclosed total of $1 billion or more or an upfront of $100 million or more. It excludes acquisitions, royalty sales and manufacturing agreements. Terms are shown as the companies disclosed them; “upfront & near-term” means the announcement combined the two, and “up to” totals include contingent milestones. Each deal was checked against the linked announcement, filing or contemporaneous report. “China-origin” marks licensors domiciled in mainland China or Hong Kong, the basis J.P. Morgan uses for its China share figures.

Sources:

1. Vision Lifesciences research: our own deal tracking and insights from our day-to-day cross-border licensing and M&A advisory work (about us)
2. J.P. Morgan, Q3 2026 Biopharma Licensing and Venture Report (Oct 2026; DealForma data through Sept. 30, 2026)
3. J.P. Morgan, Q2 2026 Biopharma Licensing and Venture Report (data through June 30, 2026)
4. J.P. Morgan, Q1 2026 Biopharma Licensing and Venture Report
5. J.P. Morgan, Q4 2025 Biopharma Licensing and Venture Report (Dec 2025)
6. VCBeat (VBInsight data), 2026 H1 Licensing Landscape: China secures 8 of the top 10 global licensing deals
7. Caixin Global, Chinese drugmakers strike record $136 billion in cross-border licensing deals (Jan 14, 2026; PharmCube data)